The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Anne Loeser(Patient-Centered Outcomes Research Institute), Aditya Bardia(UCLA Health), Mark E. Burkard(University of Wisconsin–Madison), Kevin Kalinsky(Emory University), Natalia Padron(Patient-Centered Outcomes Research Institute), Christine Hodgdon(Patient-Centered Outcomes Research Institute), Janice S. Kim(Massachusetts General Hospital), Julia Maués, Maryam B. Lustberg(Yale Cancer Center), Dejan Juric(Massachusetts General Hospital), Lesley Glenn(Patient-Centered Outcomes Research Institute), Hope S. Rugo(City of Hope), Sheila Johnson(Patient-Centered Outcomes Research Institute), Jeffrey Peppercorn(Stem Cell Institute), Kimberly Parekh(Patient-Centered Outcomes Research Institute), Andrzej Niemierko(Harvard University)
Cited by 30
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k